VEGFA and wet macular degeneration: Vascular endothelial growth factor (VEGF) is the main target for treatment of neovascular age-related macular degeneration (nAMD); thus, intravitreal injection of agent inhibiting the activity of VEGF has become the standard treatment for nAMD1–4.